Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer.

These results from our retrospective study show that HER2 therapy interruption in patients with metastatic HER2+ breast cancer, who have responded to the therapy, is associated with low risk of rapid disease progression. Study suggests that therapy interruption in cases of response and reinitiation in progression is feasible.